These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 8263940)

  • 21. Finding needles in haystacks: Reranking DOT results by using shape complementarity, cluster analysis, and biological information.
    Law DS; Ten Eyck LF; Katzenelson O; Tsigelny I; Roberts VA; Pique ME; Mitchell JC
    Proteins; 2003 Jul; 52(1):33-40. PubMed ID: 12784365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dictionary of interfaces in proteins (DIP). Data bank of complementary molecular surface patches.
    Preissner R; Goede A; Frömmel C
    J Mol Biol; 1998 Jul; 280(3):535-50. PubMed ID: 9665855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonspecific amine immobilization of ligand can Be a potential source of error in BIAcore binding experiments and may reduce binding affinities.
    Kortt AA; Oddie GW; Iliades P; Gruen LC; Hudson PJ
    Anal Biochem; 1997 Nov; 253(1):103-11. PubMed ID: 9356148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolutionary conservation in multiple faces of protein interaction.
    Choi YS; Yang JS; Choi Y; Ryu SH; Kim S
    Proteins; 2009 Oct; 77(1):14-25. PubMed ID: 19350617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydrophobic complementarity in protein-protein docking.
    Berchanski A; Shapira B; Eisenstein M
    Proteins; 2004 Jul; 56(1):130-42. PubMed ID: 15162493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid refinement of protein interfaces incorporating solvation: application to the docking problem.
    Jackson RM; Gabb HA; Sternberg MJ
    J Mol Biol; 1998 Feb; 276(1):265-85. PubMed ID: 9514726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On the role of electrostatic interactions in the design of protein-protein interfaces.
    Sheinerman FB; Honig B
    J Mol Biol; 2002 Apr; 318(1):161-77. PubMed ID: 12054776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
    J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling protein docking using shape complementarity, electrostatics and biochemical information.
    Gabb HA; Jackson RM; Sternberg MJ
    J Mol Biol; 1997 Sep; 272(1):106-20. PubMed ID: 9299341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
    Covaceuszach S; Cattaneo A; Lamba D
    Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular basis of crossreactivity and the limits of antibody-antigen complementarity.
    Arevalo JH; Taussig MJ; Wilson IA
    Nature; 1993 Oct; 365(6449):859-63. PubMed ID: 8413674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein-protein interaction at crystal contacts.
    Janin J; Rodier F
    Proteins; 1995 Dec; 23(4):580-7. PubMed ID: 8749854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering antibodies for stability and efficient folding.
    Honegger A
    Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crystallographic analysis of the NNA7 Fab and proposal for the mode of human blood-group recognition.
    Xie K; Song SC; Spitalnik SL; Wedekind JE
    Acta Crystallogr D Biol Crystallogr; 2005 Oct; 61(Pt 10):1386-94. PubMed ID: 16204891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein-protein interaction regulates proteins' mechanical stability.
    Cao Y; Yoo T; Zhuang S; Li H
    J Mol Biol; 2008 May; 378(5):1132-41. PubMed ID: 18433770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 2.5 A resolution structure of the jel42 Fab fragment/HPr complex.
    Prasad L; Waygood EB; Lee JS; Delbaere LT
    J Mol Biol; 1998 Jul; 280(5):829-45. PubMed ID: 9671553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The rational construction of an antibody against cystatin: lessons from the crystal structure of an artificial Fab fragment.
    Schiweck W; Skerra A
    J Mol Biol; 1997 May; 268(5):934-51. PubMed ID: 9180382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
    Burioni R; Bugli F; Mancini N; Rosa D; Di Campli C; Moroncini G; Manzin A; Abrignani S; Varaldo PE; Clementi M; Fadda G
    Virology; 2001 Sep; 288(1):29-35. PubMed ID: 11543655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational analyses of the surface properties of protein-protein interfaces.
    Gruber J; Zawaira A; Saunders R; Barrett CP; Noble ME
    Acta Crystallogr D Biol Crystallogr; 2007 Jan; 63(Pt 1):50-7. PubMed ID: 17164526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability.
    Röthlisberger D; Honegger A; Plückthun A
    J Mol Biol; 2005 Apr; 347(4):773-89. PubMed ID: 15769469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.